Curaleaf Holdings (CURLF) Cost of Revenue (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Cost of Revenue of $166.9 million for Q1 2026, up 10.51% year-over-year from $151.1 million in Q1 2025, and up 4.46% quarter-over-quarter from $159.8 million in Q4 2025.
Curaleaf Holdings (CURLF) Cost of Revenue (2019 - 2026) Analysis & Trends
Curaleaf Holdings' Cost of Revenue history runs 8 years deep, the most recent figure standing at $166.9 million for Q1 2026.
- In Q1 2026, Cost of Revenue rose 10.51% year-over-year to $166.9 million; the TTM figure through Mar 2026 stood at $649.2 million (down 2.6% YoY), while the FY2025 annual figure was $637.1 million, down 8.13% from the prior year.
- Cost of Revenue for Q1 2026 stood at $166.9 million, up from $159.8 million in the prior quarter.
- The five-year high for Cost of Revenue was $274.4 million in Q4 2022, with the low at $189077.0 in Q4 2023.
- The 5-year median for Cost of Revenue is $162.8 million (2024), against an average of $162.7 million.
- The sharpest annual moves came in 2023 and 2024: Cost of Revenue sank 99.93% in 2023, then surged 86456.8% in 2024.
- Curaleaf Holdings' Cost of Revenue stood at $274.4 million in 2022, then tumbled by 99.93% to $189077.0 in 2023, then soared by 86456.8% to $163.7 million in 2024, then decreased by 2.35% to $159.8 million in 2025, then grew by 4.46% to $166.9 million in 2026.
- Business Quant data shows CURLF's Cost of Revenue at $166.9 million in Q1 2026, $159.8 million in Q4 2025, and $160.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Curaleaf Holdings | 2.51 Bn | 2.42 Bn | 169.91 Mn | 170.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 170.19 Mn |
| Jun 30, 2026 | 170.19 Mn |
| Mar 31, 2026 | 166.94 Mn |
| Mar 31, 2026 | 166.94 Mn |
| Dec 31, 2025 | 159.81 Mn |
| Dec 31, 2025 | 159.81 Mn |
| Sep 30, 2025 | 160.50 Mn |
| Sep 30, 2025 | 160.50 Mn |
| Jun 30, 2025 | 161.97 Mn |
| Jun 30, 2025 | 161.97 Mn |
| Mar 31, 2025 | 151.06 Mn |
| Mar 31, 2025 | 151.06 Mn |
| Dec 31, 2024 | 163.66 Mn |
| Dec 31, 2024 | 163.66 Mn |
| Sep 30, 2024 | 170.01 Mn |
| Sep 30, 2024 | 170.01 Mn |
| Jun 30, 2024 | 181.82 Mn |
| Jun 30, 2024 | 181.82 Mn |
| Mar 31, 2024 | 178.03 Mn |
| Mar 31, 2024 | 178.03 Mn |